A systematic review of quality of life and health-related quality of life as outcomes in substance and behavioural addictions.
addictive behaviour
outcome assessment
psychometrics
quality of life
substance-related disorders
Journal
Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
30
05
2023
received:
24
01
2023
accepted:
19
06
2023
medline:
13
11
2023
pubmed:
13
7
2023
entrez:
13
7
2023
Statut:
ppublish
Résumé
Consideration of an individual's quality of life (QoL) can benefit assessment and treatment of addictive disorders, however, uncertainty remains over operationalisation of the construct as an outcome and the appropriateness of existing measures for these populations. This systematic review aimed to identify and evaluate QoL and health-related QoL outcome instruments used in addiction-related risk and harm research and map their conceptualised domains. Three electronic databases and a specialised assessment library were searched on 1 February 2022 for QoL or health-related QoL outcome instruments used with addiction-related risk and harm populations. PRISMA reporting guidance was followed and included outcome instruments were appraised using mixed methods. Psychometric evidence supporting their use was summarised. The COSMIN risk of bias tool was used to assess validation studies. A total of 298 articles (330 studies) used 53 outcome instruments and 41 unique domains of QoL. Eleven instruments' psychometric properties were evaluated. No instrument was assessed for any parameter in at least five studies for meta-analytic pooling. Cronbach's alpha (α) internal consistency was the most widely assessed parameter with the AQoLS, WHOQOL-BREF, ALQoL-9, Q-LES-Q-SF, SF-12, DUQoL, QLI and SF-36 displaying promising statistics (α > 0.70). Many instruments have been utilised. However, a significant proportion of studies applied a small number of instruments with minimal high-quality validation evidence supporting their use within addiction-related risk and harm. Promising instruments are recommended, however, the paucity of supporting evidence limits confidence in the reliability and validity of QoL measurement in these populations.
Types de publication
Systematic Review
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1680-1700Informations de copyright
© 2023 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.
Références
Peterson C, Li M, Xu L, Mikosz CA, Luo F. Assessment of annual cost of substance use disorder in US hospitals. JAMA Netw Open. 2021;4:e210242.
Jiang R, Lee I, Lee TA, Pickard AS. The societal cost of heroin use disorder in the United States. PloS One. 2017;12:e0177323.
Mohapatra S, Patra J, Popova S, Duhig A, Rehm J. Social cost of heavy drinking and alcohol dependence in high-income countries. Int J Public Health. 2010;55:149-157.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
NIDA. Other commonly used addictive substances. National Institute of Drug Abuse; 25 June 2020. https://www.drugabuse.gov/publications/media-guide/other-commonly-used-addictive-substances.
Tran BX, Moir M, Latkin CA, Hall BJ, Nguyen CT, Ha GH, et al. Global research mapping of substance use disorder and treatment 1971-2017: implications for priority setting. Subst Abuse Treat Prev Policy. 2019;14:21.
Karim R, Chaudhri P. Behavioral addictions: an overview. J Psychoactive Drugs. 2012;44:5-17.
Griffiths M. Gambling on the internet: a brief note. J Gambl Stud. 1996;12:4-71.
Grant JE, Potenza MN, Weinstein A, Gorelick DA. Introduction to behavioral addictions. Am J Drug Alcohol Abuse. 2010;36:233-241.
Toner P, Böhnke JR, Andersen P, McCambridge J. Alcohol screening and assessment measures for young people: a systematic review and meta-analysis of validation studies. Drug Alcohol Depend. 2019;202:39-49.
McKeganey N, Morris Z, Neale J, Robertson M. What are drug users looking for when they contact drug services: abstinence or harm reduction? Drugs Educ Prev Policy. 2004;11:423-435.
Lozano BE, Stephens RS, Roffman RA. Abstinence and moderate use goals in the treatment of marijuana dependence. Addiction. 2006;101:1589-1597.
Heather N, Adamson SJ, Raistrick D, Slegg GP. Initial preference for drinking goal in the treatment of alcohol problems: I. baseline differences between abstinence and non-abstinence groups. Alcohol Alcohol. 2010;45:128-135.
McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992;9:199-213.
Lesieur HR, Blume SB. Modifying the addiction severity index for use with pathological gamblers. Am J Addict. 1992;1:240-247.
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction. 1993;88:791-804.
Kelly JF, Greene MC, Bergman BG. Beyond abstinence: changes in indices of quality of life with time in recovery in a nationally representative sample of US adults. Alcohol Clin Exp Res. 2018;42:770-780.
Almeida PP, de Araujo Filho GM, Malta SM, Laranjeira RR, Marques AC, Bressan RA, et al. Attention and memory deficits in crack-cocaine users persist over four weeks of abstinence. J Subst Abuse Treat. 2017;81:73-78.
Soar K, Parrott AC, Fox HC. Persistent neuropsychological problems after 7 years of abstinence from recreational ecstasy (MDMA): a case study. Psychol Rep. 2004;95:192-196.
Morgan M, McFie L, Fleetwood L, Robinson J. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology (Berl). 2002;159:294-303.
World Health Organization. Programme on mental health: WHOQOL user manual. Geneva: World Health Organization; 1998.
Skevington SM, McCrate FM. Expecting a good quality of life in health: assessing people with diverse diseases and conditions using the WHOQOL-BREF. Health Expect. 2012;15:49-62.
Llewellyn AM, Skevington SM. Evaluating a new methodology for providing individualized feedback in healthcare on quality of life and its importance, using the WHOQOL-BREF in a community population. Qual Life Res. 2016;25:605-614.
Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA. 1995;273:59-65.
Donovan D, Mattson ME, Cisler RA, Longabaugh R, Zweben A. Quality of life as an outcome measure in alcoholism treatment research. J Stud Alcohol Suppl. 2005;15:119-139.
Laudet AB. The case for considering quality of life in addiction research and clinical practice. Addict Sci Clin Pract. 2011;6:44-55.
Luquiens A, Reynaud M, Falissard B, Aubin HJ. Quality of life among alcohol-dependent patients: how satisfactory are the available instruments? A systematic review. Drug Alcohol Depend. 2012;125:192-202.
Rudolf H, Watts J. Quality of life in substance abuse and dependency. Int Rev Psychiatry. 2002;14:190-197.
Smith KW, Larson MJ. Quality of life assessments by adult substance abusers receiving publicly funded treatment in Massachusetts. Am J Drug Alcohol Abuse. 2003;29:323-335.
Laudet AB, Morgen K, White WL. The role of social supports, spirituality, religiousness, life meaning and affiliation with 12-step fellowships in quality of life satisfaction among individuals in recovery from alcohol and drug problems. Alcohol Treat Q. 2006;24:33-73.
Tracy EM, Laudet AB, Min MO, Kim H, Brown S, Jun MK, et al. Prospective patterns and correlates of quality of life among women in substance abuse treatment. Drug Alcohol Depend. 2012;124:242-249.
Laudet AB, Becker JB, White WL. Don't wanna go through that madness no more: quality of life satisfaction as predictor of sustained remission from illicit drug misuse. Subst Use Misuse. 2009;44:227-252.
O'Sullivan D, Xiao Y, Watts JR. Recovery capital and quality of life in stable recovery from addiction. Rehabil Couns Bull. 2019;62:209-221.
Granfield R, Cloud W. Coming clean: overcoming addiction without treatment. New York: NYU Press; 1999.
Cloud W, Granfield R. A life course perspective on exiting addiction: the relevance of recovery capital in treatment. NAD Publ. 2004;44:185-202.
White W, Cloud W. Recovery capital: a primer for addictions professionals. Counselor. 2008;9:22-27.
Hewitt AJ. After the fire: post traumatic growth in recovery from addictions (Doctoral dissertation, University of Bath).
Neale J, Nettleton S, Pickering L. Gender sameness and difference in recovery from heroin dependence: a qualitative exploration. Int J Drug Policy. 2014;25:3-12.
Tiffany ST, Friedman L, Greenfield SF, Hasin DS, Jackson R. Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. Addiction. 2012;107:709-718.
Curran GM, Flynn HA, Kirchner J, Booth BM. Depression after alcohol treatment as a risk factor for relapse among male veterans. J Subst Abuse Treat. 2000;19:259-265.
Willinger U, Lenzinger E, Hornik K, Fischer G, Schönbeck G, Aschauer HN, et al. Anxiety as a predictor of relapse in detoxified alcohol-dependent patients. Alcohol Alcohol. 2002;37:609-612.
Walton MA, Blow FC, Bingham CR, Chermack ST. Individual and social/environmental predictors of alcohol and drug use 2 years following substance abuse treatment. Addict Behav. 2003;28:627-642.
Giordano AL, Clarke PB, Furter RT. Predicting substance abuse relapse: the role of social interest and social bonding. J Addict Offender Couns. 2014;35:114-127.
Higginson IJ, Carr AJ. Using quality of life measures in the clinical setting. BMJ. 2001;322:1297-1300.
Bonomi AE, Patrick DL, Bushnell DM, Martin M. Quality of life measurement will we ever be satisfied? J Clin Epidemiol. 2000;53:19-23.
Ferrans CE. Definitions and conceptual models of quality of life. Outcomes assessment in cancer: Measures, methods, and applications. Cambridge: Cambridge University Press; 2005. p. 14-30.
Costa DS, Mercieca-Bebber R, Rutherford C, Tait MA, King MT. How is quality of life defined and assessed in published research? Qual Life Res. 2021;30:2109-2121.
Mayo NE. Dictionary of quality of life and health outcomes measurement, Version 1.
Strada L, Vanderplasschen W, Buchholz A, Schulte B, Muller AE, Verthein U, et al. Measuring quality of life in opioid-dependent people: a systematic review of assessment instruments. Qual Life Res. 2017;26:3187-3200.
Schalock RL, Keith KD, Verdugo MÁ, Gómez LE. Quality of life model development and use in the field of intellectual disability. Enhancing the quality of life of people with intellectual disabilities: From theory to practice. Dordrecht: Springer; 2011. p. 17-32.
Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res. 2013;22:1889-1905.
De Maeyer J, Vanderplasschen W, Broekaert E. Quality of life among opiate-dependent individuals: a review of the literature. Int J Drug Policy. 2010;21:364-380.
Aromataris E, Munn Z. JBI manual for evidence synthesis. JBI; 2020. Available from https://synthesismanual.jbi.global, https://doi.org/10.46658/JBIMES-20-01
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269.
Analytics C. EndNote X9, Philadelphia, PA.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
World Health Organization. ICD-11: International Classification Of Diseases 11th Revision.
Mokkink LB, De Vet HC, Prinsen CA, Patrick DL, Alonso J, Bouter LM, et al. COSMIN risk of bias checklist for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27:1171-1179.
Terwee CB, Prinsen CA, Chiarotto A, Westerman MJ, Patrick DL, Alonso J, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Qual Life Res. 2018;27:1159-1170.
Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res. 2012;21:651-657.
Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60:34-42.
Prinsen CA, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, et al. How to select outcome measurement instruments for outcomes included in a “Core outcome set”-a practical guideline. Trials. 2016;17:449.
Higuchi S, Moriguchi Y, Tan KH. Psychometric validation of the Japanese version of alcohol quality of life scale (AQoLS-Japan) in the treatment of patients with alcohol use disorder. Qual Life Res. 2020;29:223-235.
Luquiens A, Whalley D, Laramée P, Falissard B, Kostogianni N, Rehm J, et al. Validation of a new patient-reported outcome instrument of health-related quality of life specific to patients with alcohol use disorder: the alcohol quality of life scale (AQoLS). Qual Life Res. 2016;25:1549-1560.
Zubaran C, Zolfaghari E, Foresti K, Emerson J, Sud R, Surjadi J. A validation study of the English version of the AlQol 9 to measure quality of life. Am J Drug Alcohol Abuse. 2014;40:131-136.
Pappa AS, Ginieri-Coccossis M, Richardson C, Charalampi A, Liappas IA, Paparrigopoulos T. Appraisal of a specific scale for quality of life (AlQoL-9) in Greek alcohol dependent individuals attending: a confirmatory factor analysis. Psychiatriki. 2016;27:17-26.
Malet L, Llorca PM, Beringuier B, Lehert P, Falissard B. AlQoL 9 for measuring quality of life in alcohol dependence. Alcohol Alcohol. 2006;41:181-187.
Chang KC, Wang JD, Tang HP, Cheng CM, Lin CY. Psychometric evaluation, using Rasch analysis, of the WHOQOL-BREF in heroin-dependent people undergoing methadone maintenance treatment: further item validation. Health Qual Life Outcomes. 2014;12:148.
Fu TS, Tuan YC, Yen MY, Wu WH, Huang CW, Chen WT, et al. Psychometric properties of the World Health Organization quality of life assessment-brief in methadone patients: a validation study in northern Taiwan. Harm Reduct J. 2013;10:37.
Zubaran C, Emerson J, Sud R, Zolfaghari E, Foresti K. The application of the drug user quality of life scale (DUQOL) in Australia. Health Qual Life Outcomes. 2012;10:31.
Bourion-Bédès S, Schwan R, Epstein J, Laprevote V, Bédès A, Bonnet JL, et al. Combination of classical test theory (CTT) and item response theory (IRT) analysis to study the psychometric properties of the French version of the quality of life enjoyment and satisfaction questionnaire-short form (Q-LES-Q-SF). Qual Life Res. 2015;24:287-293.
Bourion-Bédès S, Schwan R, Laprevote V, Bédès A, Bonnet JL, Baumann C. Differential item functioning (DIF) of SF-12 and Q-LES-Q-SF items among french substance users. Health Qual Life Outcomes. 2015;13:172.
Russo J, Roy-Byrne P, Reeder D, Alexander M, Dwyer-O'Connor ED, Dagadakis C, et al. Longitudinal assessment of quality of life in acute psychiatric inpatients: reliability and validity. J Nerv Ment Dis. 1997;185:166-175.
Daeppen JB, Krieg MA, Burnand B, Yersin B. MOS-SF-36 in evaluating health-related quality of life in alcohol-dependent patients. Am J Drug Alcohol Abuse. 1998;24:685-694.
Hsiao YY, Shih CL, Yu WH, Hsieh CH, Hsieh CL. Examining unidimensionality and improving reliability for the eight subscales of the SF-36 in opioid-dependent patients using Rasch analysis. Qual Life Res. 2015;24:279-285.
Sonntag M, König HH, Konnopka A. The responsiveness of the EQ-5D and time trade-off scores in schizophrenia, affective disorders, and alcohol addiction. Health Qual Life Outcomes. 2015;13:114.
Günther O, Roick C, Angermeyer MC, König HH. The EQ-5D in alcohol dependent patients: relationships among health-related quality of life, psychopathology and social functioning. Drug Alcohol Depend. 2007;86:253-264.
Günther OH, Roick C, Angermeyer MC, König HH. Responsiveness of EQ-5D utility indices in alcohol-dependent patients. Drug Alcohol Depend. 2008;92:291-295.
da Silva B, Lima AF, Fleck M, Pechansky F, De Boni R, Sukop P. Psychometric properties of the World Health Organization quality of life instrument (WHOQOL-BREF) in alcoholic males: a pilot study. Qual Life Res. 2005;14:473-478.
Pyne JM, Tripathi S, French M, McCollister K, Rapp RC, Booth BM. Longitudinal association of preference-weighted health-related quality of life measures and substance use disorder outcomes. Addiction. 2011;106:507-515.
Dixon J. Payment by results-new financial flows in the NHS. BMJ. 2004;328:969-970.
Mayo NE, Figueiredo S, Ahmed S, Bartlett SJ. Montreal accord on patient-reported outcomes (PROs) use series-paper 2: terminology proposed to measure what matters in health. J Clin Epidemiol. 2017;89:119-124.